Roquefort Therapeutics PLC (LON: ROQ) has agreed to sell its subsidiary, Oncogeni, to UAE-based Nations Trust Holding in a deal worth up to $12 million (£9.3 million).
Roquefort Therapeutics plc (LSE:ROQ,OTCQB:ROQAF) Midkine Antibody Licencing Deal
Roquefort Therapeutics plc (LSE: ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market is pleased to announce